ストックスクリーナーアプリを入手
0.91
5.78%
0.0497
アフターアワーズ：
.95
0.04
+4.40%
前日終値:
$0.8603
開ける：
$0.879
24時間の取引高:
614.86K
Relative Volume:
1.18
時価総額：
$74.98M
収益：
$38.70M
当期純損益:
$-117.88M
株価収益率:
-0.3346
EPS:
-2.72
ネットキャッシュフロー:
$-92.84M
1週間 パフォーマンス:
-5.68%
1か月 パフォーマンス:
-5.90%
6か月 パフォーマンス:
-33.09%
1年 パフォーマンス:
-37.67%
1日の値動き範囲:
$0.86
$0.9171
1週間の範囲:
$0.81
$0.98
52週間の値動き範囲:
$0.81
$3.77
Adicet Bio Inc Stock (ACET) Company Profile
ACET を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.91 | 74.98M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-30 | 再開されました | Guggenheim | Buy |
| 2024-09-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-06-27 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-03-31 | 開始されました | SMBC Nikko | Outperform |
| 2022-03-08 | 開始されました | Truist | Buy |
| 2022-03-04 | 開始されました | Jefferies | Buy |
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2021-04-23 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-14 | 開始されました | Canaccord Genuity | Buy |
| 2021-04-08 | 開始されました | Guggenheim | Buy |
| 2020-11-04 | 開始されました | B. Riley Securities | Buy |
| 2020-10-27 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-16 | 開始されました | Wedbush | Outperform |
すべてを表示
Adicet Bio Inc (ACET) 最新ニュース
Adicet Bio (NASDAQ:ACET) Earns Neutral Rating from HC Wainwright - Defense World
Adicet Bio doses first subject in Phase I trial of renal cell carcinoma therapy - Yahoo! Voices
Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Fmr LLC - Defense World
Adicet Bio Advances with Phase 1 Trial of ADI-270 - TipRanks
Adicet Bio's (ACET) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Adicet Bio begins trial for kidney cancer therapy - Investing.com
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - BioSpace
ACET stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
ACET stock touches 52-week low at $0.89 amid market challenges - Investing.com Canada
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - BioSpace
Adicet Bio Names Dr. Julia Maltzman As Chief Medical Officer - Contract Pharma
Adicet Bio names new Chief Medical Officer - Investing.com
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - MarketBeat
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Drops By 18.1% - Defense World
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces CAR-T challenges - Investing.com
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Rises By 6.1% - MarketBeat
Adicet Bio Awards New Employee Stock Options at $1.13 Per Share in Inducement Grant | ACET Stock News - StockTitan
Adicet Bio clears debt with Banc of California By Investing.com - Investing.com South Africa
Adicet Bio clears debt with Banc of California - Investing.com India
Adicet Bio Clears Debts with Banc of California - TipRanks
Adicet Bio Inc (NASDAQ: ACET) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
GSA Capital Partners LLP Has $56,000 Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio, Inc. Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Marketscreener.com
Adicet Bio Reports Q3 2024 Results and Clinical Progress - TipRanks
Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright - Defense World
First Patient Dosed in Trial for Adicet's T-Cell Therapy ADI-100 in Autoimmune Disease - CGTLive™
Adicet Bio To Present At Jefferies London Healthcare Conference; Webcast At 7:30 AM ET - Nasdaq
Adicet Bio begins trial for innovative cancer therapy By Investing.com - Investing.com Canada
Adicet Bio Advances Cancer and Autoimmune Trials - TipRanks
Adicet Bio begins trial for innovative cancer therapy - Investing.com
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
Adicet Bio begins lupus nephritis trial, eyes other diseases By Investing.com - Investing.com Canada
Adicet Bio's (ACET) Neutral Rating Reiterated at HC Wainwright - MarketBeat
Adicet Bio begins lupus nephritis trial, eyes other diseases - Investing.com
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - Business Wire
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Adicet Bio Launches Phase 1 Trial for Lupus Drug with FDA Fast Track Status - StockTitan
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire
Adicet Bio's ADI-001 Shows Breakthrough CAR T Cell Results in Autoimmune Treatment Study - StockTitan
Adicet Bio amends loan terms with PacWest Bank By Investing.com - Investing.com Nigeria
RA Capital Management, L.P. Expands Stake in Adicet Bio Inc - GuruFocus.com
ACET stock touches 52-week low at $1.04 amid market challenges - Investing.com
Adicet Bio To Present At Guggenheim Securities Healthcare Innovation Conference; Webcast At 3:00 PM - Nasdaq
FY2024 EPS Estimates for Adicet Bio Lowered by HC Wainwright - MarketBeat
HC Wainwright Decreases Earnings Estimates for Adicet Bio - Defense World
Wedbush Reiterates “Outperform” Rating for Adicet Bio (NASDAQ:ACET) - Defense World
Adicet Bio (NASDAQ:ACET) Announces Earnings Results, Hits Estimates - MarketBeat
Adicet Bio Expands Trial Portfolio, Secures FDA Fast Track Status Despite $30.5M Loss | ACET Stock News - StockTitan
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire
Adicet Bio to Participate in Upcoming Investor Conferences - Business Wire
Adicet Bio Inc (ACET) 財務データ
収益
当期純利益
現金流量
EPS
Adicet Bio Inc (ACET) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Jan 25 '24 |
Buy |
2.40 |
3,125,000 |
7,500,000 |
7,526,359 |
| GORDON CARL L | Director |
Jan 25 '24 |
Buy |
2.40 |
3,125,000 |
7,500,000 |
7,526,359 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):